Virology: Pushing the envelope

Primates have co-opted a viral gene to produce an envelope protein that prevents infection by the HERV-T virus and likely contributed to the extinction of this virus.
  1. Julia H Wildschutte
  2. John M Coffin  Is a corresponding author
  1. Bowling Green State University, United States
  2. Tufts University, United States

To counter the constant threat posed by viruses, vertebrate species have evolved a variety of antiviral mechanisms. In return, however, rapid mutation and turnover rates permit viruses to swiftly evolve to evade such mechanisms. This on-going ‘arms race’ between viruses and their hosts has had an important role in shaping the evolution of the species we observe today (tenOever, 2016).

Before a virus infects a cell, envelope proteins displayed on its surface must bind to a receptor located on the surface of the host cell. This receptor-envelope interaction is highly specific and, in turn, determines whether the virus is able to infect a particular cell type or species. In other words, in the absence of the receptor the virus loses its ability to infect the cell.

In a process termed ‘receptor interference’, an envelope protein from a previous viral infection can block cell receptors, preventing infection by a new virus – even an unrelated one – that also binds to that receptor (Figure 1). Remarkably, envelope proteins from such pre-infecting retroviruses can mediate receptor interference even if they have been extinct for millions of years (Boeke and Stoye, 1997). To date, clear examples of such interference have been limited to animal models, including chickens (Payne et al., 1971) and mice (Buller et al., 1987). Now, in eLife, Daniel Blanco-Melo, Robert Gifford and Paul Bieniasz of the Rockefeller University and MRC-University of Glasgow Centre for Virus Research report the first example of such interference in humans (Blanco-Melo et al., 2017).

Co-option of a viral protein for receptor interference.

Left: Cells expressing MCT1 (blue), which is the receptor for a retrovirus called HERV-T, are susceptible to infection from a virus that encodes a surface envelope protein produced by an ancestral form of HERV-T (red). Right: Our genome contains proviruses – copies of the DNA of ancient retroviruses, including HERV-T. Blanco-Melo et al. found that human cells can still produce envelope proteins from their copy of the env gene of the HERV-T provirus. These envelope proteins protect the cells from the resurrected virus by blocking the MCT1 receptors directly, or through the degradation of the resulting receptor-protein complex.

When a retrovirus infects a cell it integrates a DNA copy of its own genome (called a provirus) into the host cell’s genome. Because retroviruses occasionally infect germ line cells, the infection may lead to a provirus that is passed to offspring, and that can sometimes become fixed in the population. We refer to such proviruses as ‘endogenous retroviruses’. Over millions of years, large numbers of endogenous retroviruses have accumulated within vertebrate genomes, including humans, thus providing a ‘fossil record’ of previously circulating retroviruses that covers vast evolutionary scales.

While the majority of endogenous retrovirus lineages are ancient and now contain many mutations, recently formed examples tend to more closely resemble their infectious counterparts. This similarity means that, unless it is harmful, an endogenous retrovirus may retain the ability to produce functional RNA and protein products for long periods of time. Indeed, a few such endogenous retroviruses have been ‘co-opted’ to produce RNA or proteins that benefit the host (Ting et al., 1992; Mi et al., 2000; Stoye and Coffin, 2000).

The HERV-T lineage of endogenous retroviruses is an ancient member of a large group of retroviruses called gammaretroviruses (which includes leukemia viruses that affect cats and rodents). As detailed by Blanco-Melo et al., the HERV-T ancestor appears to have first invaded primate germlines about 43 to 32 million years ago, with the last invasion happening around 8 million years ago. Why did this lineage become extinct? Blanco-Melo et al. used an approach known as ‘paleovirology’ (Emerman and Malik, 2010) to begin to investigate this question.

By assessing the distribution of fossilized endogenous retroviruses among modern primate species, Blanco-Melo et al. identified a single HERV-T locus that appeared in the germline approximately 19 to 7 million years ago, whose envelope (env) gene, remarkably, has retained the ability to be translated. As other genes in the same provirus have been inactivated by mutations, this observation strongly suggests that this env gene has been selectively retained. However, its product cannot perform any ‘normal’ retroviral functions. Why, then, should this gene have been so clearly preserved throughout evolution?

Blanco-Melo et al. reconstructed an ancestral HERV-T sequence from the HERV-T proviruses found in the genomes of modern humans and other primates. A variety of cell lines could be infected by reconstructed viruses that encoded the ancestral env product, but those cells that had the version of env that is found in the host were resistant to infection. Blanco-Melo et al. then demonstrated that the product of the host-maintained env gene is able to block infection by viruses that encode the ancestral env gene by depleting the receptor they identified as MCT-1 (monocarboxylate transporter-1) from the surface of the host cell. The results imply that the HERV-T env gene in the host was co-opted and selected for antiviral protection through receptor interference.

The work from Blanco-Melo et al. highlights how endogenous retroviruses can act as raw material for potential use by the host in the host-virus arms race. This result raises the issue of the extent to which the co-option of endogenous retrovirus coding material for antiviral protection is widespread among vertebrates. Could such maintained env genes have contributed to the apparent extinction of other infectious retroviruses in the lineage leading to contemporary humans? We are eager to see whether the HERV-T picture represents a predictable pattern among endogenous retroviruses in other vertebrate lineages.

References

    1. Boeke JD
    2. Stoye JP
    (1997)
    Retroviruses
    Retrotransposons, Endogenous Retroviruses, and the Evolution of Retroelements, Retroviruses, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press.
    1. Buller RS
    2. Ahmed A
    3. Portis JL
    (1987)
    Identification of two forms of an endogenous murine retroviral env gene linked to the rmcf locus
    Journal of Virology 61:29–34.

Article and author information

Author details

  1. Julia H Wildschutte

    Department of Biological Sciences, Bowling Green State University, Bowling Green, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6096-750X
  2. John M Coffin

    Department of Molecular Biology and Microbiology, Tufts University, Boston, United States
    For correspondence
    john.coffin@tufts.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3856-762X

Publication history

  1. Version of Record published: April 13, 2017 (version 1)

Copyright

© 2017, Wildschutte et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,314
    Page views
  • 177
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Julia H Wildschutte
  2. John M Coffin
(2017)
Virology: Pushing the envelope
eLife 6:e26397.
https://doi.org/10.7554/eLife.26397

Further reading

    1. Evolutionary Biology
    Deny Cabezas-Bratesco et al.
    Research Article Updated

    Transient receptor potential (TRP) proteins are a large family of cation-selective channels, surpassed in variety only by voltage-gated potassium channels. Detailed molecular mechanisms governing how membrane voltage, ligand binding, or temperature can induce conformational changes promoting the open state in TRP channels are still a matter of debate. Aiming to unveil distinctive structural features common to the transmembrane domains within the TRP family, we performed phylogenetic reconstruction, sequence statistics, and structural analysis over a large set of TRP channel genes. Here, we report an exceptionally conserved set of residues. This fingerprint is composed of twelve residues localized at equivalent three-dimensional positions in TRP channels from the different subtypes. Moreover, these amino acids are arranged in three groups, connected by a set of aromatics located at the core of the transmembrane structure. We hypothesize that differences in the connectivity between these different groups of residues harbor the apparent differences in coupling strategies used by TRP subgroups.

    1. Evolutionary Biology
    2. Medicine
    Jingsong Zhang et al.
    Research Article

    Background:

    Abiraterone acetate is an effective treatment for metastatic castrate-resistant prostate cancer (mCRPC), but evolution of resistance inevitably leads to progression. We present a pilot study in which abiraterone dosing is guided by evolution-informed mathematical models to delay onset of resistance.

    Methods:

    In the study cohort, abiraterone was stopped when PSA was <50% of pretreatment value and resumed when PSA returned to baseline. Results are compared to a contemporaneous cohort who had >50% PSA decline after initial abiraterone administration and met trial eligibility requirements but chose standard of care (SOC) dosing.

    Results:

    17 subjects were enrolled in the adaptive therapy group and 16 in the SOC group. All SOC subjects have progressed, but four patients in the study cohort remain stably cycling (range 53–70 months). The study cohort had significantly improved median time to progression (TTP; 33.5 months; p<0.001) and median overall survival (OS; 58.5 months; hazard ratio, 0.41, 95% confidence interval (CI), 0.20–0.83, p<0.001) compared to 14.3 and 31.3 months in the SOC cohort. On average, study subjects received no abiraterone during 46% of time on trial. Longitudinal trial data demonstrated the competition coefficient ratio (αRSSR) of sensitive and resistant populations, a critical factor in intratumoral evolution, was two- to threefold higher than pre-trial estimates. Computer simulations of intratumoral evolutionary dynamics in the four long-term survivors found that, due to the larger value for αRSSR, cycled therapy significantly decreased the resistant population. Simulations in subjects who progressed predicted further increases in OS could be achieved with prompt abiraterone withdrawal after achieving 50% PSA reduction.

    Conclusions:

    Incorporation of evolution-based mathematical models into abiraterone monotherapy for mCRPC significantly increases TTP and OS. Computer simulations with updated parameters from longitudinal trial data can estimate intratumoral evolutionary dynamics in each subject and identify strategies to improve outcomes.

    Funding:

    Moffitt internal grants and NIH/NCI U54CA143970-05 (Physical Science Oncology Network).